Persistent replication of SARS-CoV-2 in a severely immunocompromised patient treated with several courses of remdesivir

Int J Infect Dis. 2021 Mar:104:379-381. doi: 10.1016/j.ijid.2020.12.050. Epub 2020 Dec 21.

Abstract

Microbiological response of SARS-CoV-2 to remdesivir in immunocompromised patients has not been evaluated. We present the case of a severely immunocompromised patient with persistent replication of SARS-CoV-2, who required different courses of remdesivir. Short courses of remdesivir might be insufficient in immunocompromised patients due to prolonged viral clearance.

Keywords: COVID-19; Immunosuppression; Lymphoma; Remdesivir; SARS-CoV-2.

Publication types

  • Case Reports

MeSH terms

  • Adenosine Monophosphate / administration & dosage
  • Adenosine Monophosphate / analogs & derivatives*
  • Adult
  • Alanine / administration & dosage
  • Alanine / analogs & derivatives*
  • Antiviral Agents / administration & dosage*
  • COVID-19 / diagnosis
  • COVID-19 / virology
  • COVID-19 Drug Treatment*
  • Female
  • Humans
  • Immunocompromised Host
  • SARS-CoV-2 / drug effects
  • SARS-CoV-2 / physiology*
  • Virus Replication / drug effects*

Substances

  • Antiviral Agents
  • remdesivir
  • Adenosine Monophosphate
  • Alanine